New law paves way for CBD market’s continued growth

Print Friendly, PDF & Email
WASHINGTON — Hemp-based cannabidiol (CBD) is poised to move further into the mainstream in 2019 after Congress renewed the U.S. Farm Bill last month and President Trump signed the legislation into law.

The legislation, which charts a course for federal farm policy and funds programs administered by the Department of Agriculture, also removed industrial hemp from a list of federally controlled substances. That provision makes CBD legal if it is derived from legally grown hemp.

No state has yet managed to get a system up and running for legalized hemp cultivation. The Farm Bill provision to deschedule hemp, championed by Republican Sen. Mitch McConnell of Kentucky, paves the way for states to establish their own regulatory frameworks for growing hemp.

CBD is a nonpsychoactive chemical found in marijuana and hemp plants that is marketed as an aid in maintaining healthy lifestyles, a treatment for a range of chronic illnesses and conditions, and an option for nonopioid pain management.

Consumer packaged goods companies across a range of categories are contemplating CBD-infused products for humans and pets. Advocates tout CBD as a source of relief from pain, anxiety and depression. CBD is also said to stimulate appetite and have anti-inflammatory and anti-acne properties.

To date, the Food and Drug Administration hasn’t approved hemp CBD supplements, food or cosmetics, but it has given the green light to cannabidiol to treat epilepsy under the pharmaceutical brand Epidiolex.



Comments are closed.